Shanghai OPM Biosciences Co., Ltd. (SHA:688293)
China · Delayed Price · Currency is CNY 52.73
-2.58 (-4.66%)
At close: Apr 21, 2026
Shanghai OPM Biosciences Revenue
In the year 2025, Shanghai OPM Biosciences had annual revenue of 354.91M CNY with 19.40% growth. Shanghai OPM Biosciences had revenue of 83.39M in the quarter ending December 31, 2025, with 2.46% growth.
Revenue
354.91M
Revenue Growth
+19.40%
P/S Ratio
20.69
Revenue / Employee
1.08M
Employees
64
Market Cap
7.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 354.91M | 57.67M | 19.40% |
| Dec 31, 2024 | 297.24M | 54.12M | 22.26% |
| Dec 31, 2023 | 243.12M | -51.24M | -17.41% |
| Dec 31, 2022 | 294.37M | 81.68M | 38.41% |
| Dec 31, 2021 | 212.68M | 87.71M | 70.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 3.17B |
| Anhui Huaheng Biotechnology | 2.86B |
| Xiangxue Pharmaceutical | 1.47B |
| Nanjing Vazyme Biotech | 1.38B |
| Chengdu Kanghua Biological Products | 1.21B |
| Wuhan Keqian Biology Co.,Ltd | 949.74M |
| R&G PharmaStudies | 851.01M |
| Acrobiosystems | 794.52M |